Skip to main content
. 2020 Mar 4;43(5):1467–1478. doi: 10.3892/or.2020.7531

Figure 1.

Figure 1.

Expression analysis of WIPI2 based on the UALCAN platform. (A) Pan-cancer analysis of WIPI2 expression across cancers from the UALCAN platform. BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, Kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PAAD, pancreatic adenocarcinoma; PRAD, prostate adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; THCA, thyroid carcinoma; THYM, thymoma; STAD, stomach adenocarcinoma; UCEC, uterine corpus endometrial carcinoma. **P<0.01, ***P<0.001. (B) The WIPI2 level was higher in tumor tissues compared with that in normal tissues. ***P<0.001. (C) Survival probability revealed that high WIPI2 expression predicted poor prognosis, P<0.05. WIPI2, WD repeat domain phosphoinositide-interacting protein 2.